283 related articles for article (PubMed ID: 31702822)
1. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
[TBL] [Abstract][Full Text] [Related]
2. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
[TBL] [Abstract][Full Text] [Related]
4. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
5. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.
Lelliott EJ; Cullinane C; Martin CA; Walker R; Ramsbottom KM; Souza-Fonseca-Guimaraes F; Abuhammad S; Michie J; Kirby L; Young RJ; Slater A; Lau P; Meeth K; Oliaro J; Haynes N; McArthur GA; Sheppard KE
Sci Rep; 2019 Feb; 9(1):1225. PubMed ID: 30718660
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
[TBL] [Abstract][Full Text] [Related]
7. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ
J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771
[TBL] [Abstract][Full Text] [Related]
8. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
Atay C; Kwak T; Lavilla-Alonso S; Donthireddy L; Richards A; Moberg V; Pilon-Thomas S; Schell M; Messina JL; Rebecca VW; Xiao M; Tan J; Zhang G; Weber JS; Herlyn M; Sarnaik AA; Gabrilovich DI
Clin Cancer Res; 2019 May; 25(9):2783-2794. PubMed ID: 30765391
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
10. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Liu C; Peng W; Xu C; Lou Y; Zhang M; Wargo JA; Chen JQ; Li HS; Watowich SS; Yang Y; Tompers Frederick D; Cooper ZA; Mbofung RM; Whittington M; Flaherty KT; Woodman SE; Davies MA; Radvanyi LG; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2013 Jan; 19(2):393-403. PubMed ID: 23204132
[TBL] [Abstract][Full Text] [Related]
11. Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.
Steinberg SM; Shabaneh TB; Zhang P; Martyanov V; Li Z; Malik BT; Wood TA; Boni A; Molodtsov A; Angeles CV; Curiel TJ; Whitfield ML; Turk MJ
Cancer Res; 2017 Apr; 77(7):1599-1610. PubMed ID: 28202513
[TBL] [Abstract][Full Text] [Related]
12. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
[TBL] [Abstract][Full Text] [Related]
13. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
14. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
Wilmott JS; Long GV; Howle JR; Haydu LE; Sharma RN; Thompson JF; Kefford RF; Hersey P; Scolyer RA
Clin Cancer Res; 2012 Mar; 18(5):1386-94. PubMed ID: 22156613
[TBL] [Abstract][Full Text] [Related]
15. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H
Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292
[TBL] [Abstract][Full Text] [Related]
16. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
17. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
Babagana M; Johnson S; Slabodkin H; Bshara W; Morrison C; Kandel ES
Mol Carcinog; 2017 May; 56(5):1515-1525. PubMed ID: 28052407
[TBL] [Abstract][Full Text] [Related]
18. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
Mohapatra P; Prasad CP; Andersson T
Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
